Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Open-Label Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Next Previous
X
Search
Trial Profile

A Phase 3, Randomized, Open-Label Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Risankizumab (Primary)
  • Indications Erythrodermic psoriasis; Generalised pustular psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms IMMspire
  • Sponsors AbbVie

    • Most Recent Events

    • 01 Feb 2023 Primary endpoint has been met (Percentage of Participants With Erythrodermic Psoriasis (EP) Achieving EP Clinical Response at Week 16) , according to Results published in the Journal of Dermatology
    • 01 Feb 2023 Primary endpoint has been met (Percentage of Participants With Generalized Pustular Psoriasis (GPP) Achieving GPP Clinical Response at Week 16) , according to Results published in the Journal of Dermatology
    • 01 Feb 2023 Results of primary analysis and 180-week follow-up safety and efficacy data published in the Journal of Dermatology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top